ARV ASSISTED LIVING INC Form SC 13E3/A February 20, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13E-3

(Rule 13e-100)

Rule 13e-3 Transaction Statement

under Section 13(e) of the Securities Exchange Act of 1934

(Amendment No. 1)

ARV Assisted Living, Inc.

(Name of the Issuer)

Prometheus Assisted Living LLC

LF Strategic Realty Investors II L.P.

LFSRI II Alternative Partnership L.P.

LFSRI II-CADIM Alternative Partnership L.P.

Lazard Frères Real Estate Investors L.L.C.

Jenny Merger Corp.

ARV Assisted Living, Inc.

Douglas M. Pasquale

(Names of Persons Filing Statement)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

00204C107

(CUSIP Number of Class of Securities)

Marjorie L. Reifenberg, Esq. Douglas M. Pasquale

Lazard Frères Real Estate Investors L.L.C. Chief Executive Officer

30 Rockefeller Plaza ARV Assisted Living, Inc.

New York, New York 10020 245 Fischer Avenue, D-1

(212) 632-6000 Costa Mesa, California 92626

(714) 751-7400

(Names, Addresses, and Telephone Numbers of Persons Authorized to

Receive Notices and Communications on Behalf of Persons Filing Statement)

With copies to:

Lee S. Parks, Esq. Douglas Armstrong, Esq.

Fried, Frank, Harris, Shriver & Jacobson Senior Vice President, Secretary and General Counsel

One New York Plaza ARV Assisted Living, Inc.

New York, New York 10004 245 Fischer Avenue, D-1

(212) 859-8000 Costa Mesa, California 92626

(714) 751-7400

This statement is filed in connection with (check the appropriate box):						
a.	x	The filing of solicitation materials or an information sthe Securities Exchange Act of 1934.	tatement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under			
b.		The filing of a registration statement under the Securi	ties Act of 1933.			
c.		A tender offer.				
d.		None of the above.				
Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: x						
Check the following box if the filing is a final amendment reporting the results of the transaction: "						
CALCULATION OF FILING FEE						
Transaction valuation* Amount of filing fee						
		\$43,841,643	\$4,034			
*	Estimated for the purposes of calculating the amount of the filing fee only. Proposed maximum aggregate value of transaction: \$43,841,643 (calculated on the basis of (1) 9,864,620 outstanding shares of common stock that will receive the merger consideration multiplied by the transaction price of \$3.90, plus (2) the product of (A) 2,386,500 shares of common stock which are subject to options to purchase shares with an exercise price of less than \$3.90 per share and (B) the difference between \$3.90 per share and the exercise price of such options).					
X			xchange Act Rule 0-11(a)(2) and identify the filing with which the offsetting ration statement number, or the Form or Schedule and the date of its filing.			
Amount Previously Paid: \$4,034						
Amo	unt Pre	viously Paid: <u>\$4,034</u>				

Filing Party: ARV Assisted Living, Inc.

Date Filed: February 12, 2003

Introduction

This Amendment No.1 to Schedule 13E-3 amends and supplements the Rule 13e-3 Transaction Statement on Schedule 13E-3 (the Initial 13E-3) filed with the U.S. Securities and Exchange Commission on February 12, 2003 by Prometheus Assisted Living LLC (Prometheus), Jenny Merger Corp., a wholly owned subsidiary of Prometheus (Merger Sub), their affiliates, LF Strategic Realty Investors II L.P., LFSRI II Alternative Partnership L.P., LFSRI II-CADIM Alternative Partnership L.P. and Lazard Frères Real Estate Investors L.L.C., ARV Assisted Living, Inc. (ARV), a Delaware corporation and the issuer of the equity securities that are the subject of a Rule 13e-3 transaction, and Douglas M. Pasquale, Chairman and Chief Executive Officer of ARV, in connection with the Agreement and Plan of Merger, dated as of January 3, 2003, by and among Prometheus, Merger Sub and ARV (the Agreement). Pursuant to the Agreement, Merger Sub will merge with and into ARV, with ARV as the surviving corporation.

Item	16	H'x	hi	hite

Item 1016 of Regulation M-A.

(c)(2) Fairness Opinion Presentation by Cohen & Steers to the Special Committee of the Board of Directors of ARV, dated January 3, 2003 (including all appendices thereto)*

* This exhibit (c)(2) replaces and supercedes exhibit (c)(2) contained in the Initial 13E-3.

SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 20, 2003

PROMETHEUS ASSISTED LIVING LLC

By: LF Strategic Realty Investors II L.P.,

LFSRI II Alternative Partnership L.P., and

LFSRI II-CADIM Alternative Partnership L.P.,

its managing members

By: Lazard Frères Real Estate Investors L.L.C.,

their general partner

By: /s/ John A.

Moore

Name: John A.

Moore

Title: Managing

Principal and

Chief

Financial Officer

LF STRATEGIC REALTY INVESTORS II L.P.

By: Lazard Frères Real Estate Investors L.L.C.,

its general partner

By: /s/ John A.

Moore

Name: John A. Moore

Title: Managing Principal and

Chief Financial

Officer

LFSRI II ALTERNATIVE PARTNERSHIP L.P.

By: Lazard Frères Real Estate Investors L.L.C.,

its general partner

By: /s/ John A. Moore

Name: John A.

Moore

Title: Managing Principal and

Chief Financial

Officer

LFSRI II-CADIM ALTERNATIVE PARTNERSHIP L.P.

By: Lazard Frères Real Estate Investors L.L.C.,

its general partner

By: /s/ John A.

Moore

Name: John A.

Moore

Title: Managing

Principal and

Chief

Financial Officer

LAZARD FRÉRES REAL ESTATE INVESTORS L.L.C.

By: /s/ John A.

Moore

Name: John A. Moore

Title: Managing

Principal and

Chief Financial

Officer

JENNY MERGER CORP.

By: /s/ John A.

Moore

Name: John A. Moore

Title: Vice President

and

Chief Financial

Officer

ARV ASSISTED LIVING, INC.

By:

/s/ Douglas M. Pasquale

Name: Douglas M. Pasquale

Title: Chief Executive

Officer

/s/ Douglas M. Pasquale

Douglas M. Pasquale

Exhibit Index

Exhibit Number	Description		
(c)(2)	Fairness Opinion Presentation by Cohen & Steers to the Special Committee of the Board of Directors of ARV, dated January 3, 2003 (including all appendices thereto)*		

^{*} This exhibit (c)(2) replaces and supercedes exhibit (c)(2) contained in the Initial 13E-3.